Related Experiment Video

Updated: Jul 10, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas

Walter Rhomberg1, Helmut Eiter, Franz Schmid

  • 1Department of Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, Feldkirch, 6800, Austria. walter.rhomberg@gmx.at

Clinical & Experimental Metastasis
|October 13, 2007
PubMed
Abstract

Insights

Razoxane and vindesine combined with radiotherapy significantly reduced new metastases and prolonged survival in advanced soft tissue sarcoma (STS) patients. This trimodal treatment is feasible and effective for unresectable and early metastatic STS.

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Razoxane and vindesine demonstrated efficacy in suppressing distant metastasis in preclinical models.
  • These agents target key mechanisms within the metastatic cascade.
  • A pilot study investigated their impact on metastasis dynamics in advanced soft tissue sarcomas (STS).

Purpose of the Study:

  • To evaluate the influence of razoxane and vindesine on metastasis progression in advanced STS.
  • To update findings from a pilot study on the efficacy of combined modality treatment.

Main Methods:

  • A cohort of 23 patients with unresectable or oligometastatic STS received razoxane and vindesine, with radiotherapy and occasional surgery.
  • New metastases were quantified at 6 and 9 months.
  • A retrospective control group of 36 STS patients received contemporary chemotherapy.

Main Results:

  • The razoxane and vindesine group showed a median of 0 new metastases at 6 and 9 months, versus 4.5 and 9 in controls (P < 0.001).
  • Progression-free survival at 6 months was 74% (study) vs. 23% (controls).
  • Median survival was 20+ months (study) vs. 9 months (controls) (P < 0.001), with manageable toxicity.

Conclusions:

  • Trimodal therapy with razoxane, vindesine, and radiotherapy is a feasible treatment option for unresectable and early metastatic STS.
  • This combination effectively inhibits the development of distant metastases in most patients.
  • The treatment regimen leads to a significant prolongation of patient survival.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...